Key takeaway: Granules India Limited's earnings call on September 29, 2026, outlined the company's strategic transformation and growth initiatives. Management emphasized a shift from past challenges to a new growth phase, driven by investments in manufacturing, R&D, and product development. The company highlighted four growth engines: controlled substances, complex generics, oncology, and peptide CDMO. In controlled substances, Granules has become the third-largest manufacturer in the U.S., with a focus on ADHD medications and expanding market share through DEA quota increases and supply chain resilience. For complex generics, the company noted a significant increase in revenue contribution, from 1% in fiscal 20 to 33% in fiscal 26, driven by a selective first-to-file strategy. In oncology, the company is prioritizing differentiated molecules with early market entry, leveraging its API and formulation capabilities. The peptide CDMO business, acquired through Senn Tides, aims for $50 million in annual revenue in three years, with plans to expand into oligonucleotides and ADCs. Financially, the company reported improved gross and EBITDA margins, with a focus on disciplined capital allocation for future growth. Management also addressed challenges like raw material costs and DEA compliance, emphasizing their strong track record and strategic focus on high-value products. The call concluded with Q&A sessions addressing product pipelines, market expansion, and operational strategies.

Key takeaway: Granules India Limited held its Q1 FY27 earnings conference call on July 21, 2026, where management highlighted a 22% year-on-year revenue growth to INR 1,477 crores, marking the strongest first quarter in the company's history. Gross margins remained healthy at 65.6%, and EBITDA grew 37% to INR 339 crores. Management reported a significant improvement in return on capital to 18% and noted that net debt to EBITDA was nearly zero. The company emphasized its transition to an innovation-led pharmaceutical platform, with complex generics now comprising 50% of finished dosages. Management also discussed ongoing remediation efforts at the Gagillapur facility, stating that they had met FDA requirements and were ready for inspections. Future growth strategies include scaling up the Genome Valley facility and expanding the peptide CDMO platform. The call concluded with a Q&A session addressing various operational and financial queries.

Key takeaway: Granules India Limited held its Q4 and FY '26 earnings conference call on April 29, 2026, where management reported a year of deliberate reset and measurable progress. The company stabilized performance and strengthened execution after a period of regulatory correction. Management highlighted that the GPI facility in Virginia reached its operating potential, and the acquisition of Senn Chemicals contributed positively to the business. Financially, FY '26 revenue grew by 20% year-on-year, with a gross margin expansion to 65%. The fourth quarter saw a positive EBITDA for the peptide CDMO business. Management emphasized ongoing improvements in compliance and quality systems, alongside a commitment to safety and sustainability. The company also reported a reduction in net debt and maintained a focus on R&D for complex generics. Overall, management expressed confidence in the company's strengthened foundation for future growth.